We investigated the correlation between in vitro susceptibility to fluconazole and clinical response in severely ill patients with oropharyngeal candidiasis treated with fluconazole. The study included 48 adult patients, of whom 23 were neutropenic (absolute neutrophil count, õ500/mm 3 ). Forty-eight isolates (20 Candida albicans, 12 Candida krusei, 10 Candida kefyr, 3 Torulopsis glabrata, and 3 Candida tropicalis) were tested for susceptibility to fluconazole with use of the macrodilution method of the National Committee for Clinical Laboratory Standards. A strain was considered to be susceptible to fluconazole if the MIC was £8 mg/mL and resistant if the value was §64 mg/mL. All but one of the resistant strains were C. krusei isolates. Species of causative Candida, persistent neutropenia, and susceptibility to fluconazole were significant predictors of clinical response by univariate analysis. Logistic regression analysis indicated that the only significant factor was the species of Candida isolates, validating the recently recommended MIC breakpoint and the correlation between clinical outcome and in vitro antifungal susceptibility.
A reference method for in vitro susceptibility testing of response in severely ill patients with oropharyngeal candidiasis treated with fluconazole. yeasts has been proposed and recently approved by the National Committee for Clinical Laboratory Standards (NCCLS) [1] . This progress has been followed by research focusing on three
Patients and Methods main topics: definition of a less labor-intensive method [2 -4], determination of relevant interpretive MIC breakpoints for

Patients
antifungals, and assessment of the correlation of the clinical
The study group consisted of 48 adult patients who were outcome with in vitro results [5] .
severely ill due to various underlying disorders and were treated Establishing the clinical relevance of in vitro results has been with fluconazole for oropharyngeal candidiasis. The patients a complicated issue, since the antifungal susceptibility pattern were categorized according to the underlying disease: hematois not the only factor influencing clinical outcome [6] . In any logic malignancy, nonhematologic malignancy, or nonmaligparticular patient, pharmacokinetic properties of the antifungal nant disorder. Patients with more than one underlying disease drug as well as several host factors, such as underlying disease were categorized according to the one for which the prognosis and immune status, also determine the fate of the infection.
was worst (table 1) . Thus, an infection caused by a susceptible organism may fail Clinical diagnosis of oropharyngeal candidiasis was estabto respond to antifungal therapy; conversely, an infection due to lished by the presence of removable pearly white elevated a resistant strain usually -but not always -results in clinical patches on the mucosal surface, together with one or more failure. Proposal of a tentative MIC breakpoint value for evaluadditional signs and symptoms such as erythema, a burning ation of in vitro results, on the other hand, requires determinasensation, and pain. The diagnosis was confirmed microbiologition of distribution of susceptibility levels of the infecting specally by visualization of yeast cells and/or hyphae or pseudohycies and pharmacokinetic properties of the antifungal drug [7] . phae on gram-stained smears prepared from swabs of the visible The present study was conducted to investigate the correlalesion(s) and by isolation of Candida species. Patients whose tion between in vitro fluconazole susceptibility and clinical oral swab cultures failed to yield a Candida species were excluded from the study. The patients were monitored for neutropenia (absolute neutrophil count in peripheral blood, õ500/mm 3 ) at the beginning fied as C. albicans and non-albicans Candida. All these variables were categorical except age. The association between outcome and explanatory variables was analyzed with the x 2 test, and odds ratios and corresponding 95% confiwas evaluated clinically as a treatment success or failure acdence intervals were calculated. Logistic regression analysis cording to the disappearance or persistence of the visible oral was used to adjust the effect of intercorrelation between explanlesion(s) and other signs and symptoms related to candidiasis. atory variables on clinical response. Variables were selected by means of the forward stepwise method (removal of the variables was based on the likelihood-ratio statistics).
Microbiological Methods
Entry and removal criteria were defined as P values less than .05 and .10, respectively. The model worked as follows.
Isolation. Sabouraud dextrose agar (SDA) was used for
The variable with the smallest P value, if less than .05, was isolation of the strains from the oral swab samples of the paentered first in the model. Then, this variable was tested for tients. In cases involving a positive germ tube test [8] , the removal on the basis of the removal criteria defined above. If strain was identified as Candida albicans. The API 20C system it remained in the model, then other variables were tested for (bioMérieux, Marcy l'Etoile, France) was used for species entry. Following the entry of a new variable, all previously identification if the germ tube test was negative. The isolates entered variables were retested for removal. The selection prowere stored at 070ЊC until testing and were subcultured on cess stopped when no variables could be entered or removed. SDA at 35ЊC prior to the antifungal susceptibility assay.
The 
Results
tions caused by C. glabrata were treated successfully with fluconazole. Of the 48 patients included in the study, 30 (62%) had a All patients failing to respond to fluconazole therapy had hematologic malignancy, 10 (21%) had a solid tumor, and 8 received oral or parenteral fluconazole within the previous 2 (17%) had a nonmalignant illness. Other characteristics of the months of the current treatment. The daily dose of fluconazole patients and their underlying diseases are shown in table 1.
for these therapies had ranged between 100 mg and 200 mg. While 23 patients remained neutropenic, 25 recovered from All patients (n Å 6) but one with C. krusei infections that neutropenia during the course of antifungal therapy or were did not respond to fluconazole had persistent neutropenia and nonneutropenic at the time of initiation of therapy and remained The only patient without neutropenia had nasopharyngeal isolates were 0.25 mg/mL and 1 mg/mL, respectively, within a carcinoma and was treated locally with oral nystatin and bicarrange of £0.125 -2 mg/mL. For C. kefyr isolates, MIC 50 and bonate gargles. The patient responded clinically, but C. krusei MIC 90 values were 1 mg/mL and 4 mg/mL, respectively (range, was persistently isolated. Six weeks later, clinical infection 0.125 -8 mg/mL). MICs against all C. krusei and one of three reappeared and was treated with amphotericin B. C. glabrata isolates were ¢64 mg/mL. The MIC range for
The two patients with infections due to fluconazole-suscepti-C. glabrata was 8 -64 mg/mL. For all C. tropicalis strains, the ble C. glabrata (MIC, 8 mg/mL) were given fluconazole (400 MIC of fluconazole was 0.50 mg/mL. None of the MICs against mg/d) parenterally. The lesions healed, but the yeast persisted the Candida strains were 16 mg/mL or 32 mg/mL.
in the oral cavity. The other patient who was infected with a Clinical response to fluconazole, with respect to in vitro resistant C. glabrata strain and had persistent neutropenia was susceptibility of the isolated strains and the course of neutrocured with parenteral amphotericin B. penia, is documented in table 2. Thirty-four patients (71%) Two patients with acute myeloblastic leukemia were infected responded to fluconazole therapy, of whom 13 (38%) were with susceptible C. tropicalis strains (MIC of fluconazole, 0.50 consistently neutropenic during the course of antifungal treatmg/mL). One of these patients was also unresponsive to parenment. Of the 12 patients infected with C. krusei, 6 (50%), teral amphotericin B but improved upon recovery from neutroincluding 3 patients with persistent neutropenia, were successpenia. The other patient received fluconazole (400 mg/d) intrafully treated with fluconazole. The success rates for patients venously, resulting in clinical improvement, but cultures of infected with C. albicans, C. kefyr, and C. tropicalis were 95%, oral swab specimens were persistently positive. 80%, and 33%, respectively.
Of the two patients infected with susceptible C. kefyr (MICs Among patients with C. albicans infections, only one failed of fluconazole, 1 mg/mL and 2 mg/mL), the one with persistent to respond to fluconazole therapy, in spite of the resolution of neutropenia was treated with parenteral amphotericin B and neutropenia and recovery of a fluconazole-susceptible isolate. A patient with aplastic anemia and oropharyngeal candidiasis The associations between susceptibility to fluconazole, species of infecting Candida, and clinical response presented a caused by a susceptible strain of C. albicans (MIC of fluconazole, 1 mg/mL) was given parenteral amphotericin B. No improvement different picture. All 20 C. albicans strains were susceptible to fluconazole, of which 19 (95%) were associated with clinical was noted, and the patient died after 8 days of therapy.
The results of the statistical analysis by univariate model success. However, for patients infected with non-albicans Candida, susceptibility to fluconazole did not affect the outcome indicated that a better clinical response could be achieved in patients infected with C. albicans than in those infected with of therapy (P Å .46). Consequently, logistic regression analysis found the species of infecting Candida to be the only factor a non-albicans Candida strain (OR, 16.5; 95% CI, 1.9 -140.4; P Å .002). Recovery from neutropenia (OR, 4.1; 95% CI, 1.1 -significant for clinical outcome. 15.6; P Å .04) and susceptibility to fluconazole (OR, 4.7; 95% CI, 1.2 -18.3; P Å .02) were significant predictors of a favorable clinical outcome (table 3) . The gender and age of the Discussion patients and the type of underlying disease did not seem to Candidal infections have become a life-threatening problem have an effect on the outcome. When the effects of relationships in immunocompromised patients, mainly because of prolonged between these variables on clinical response were adjusted by use of antibiotics, wide application of indwelling central venous means of the above-described logistic regression model, the catheters, and administration of intensive chemotherapeutic only significant factor was the species of Candida isolates regimens [11] . The antifungals used in management of candidal recovered (OR, 16.4; 95% CI, 1.9 -140.1; P Å .01).
infections are limited [12] . Fluconazole is a bistriazole comThe cause of discrepancy between univariate and multivaripound that offers some advantages in the treatment of candidiaate approaches regarding the significance of recovery from sis: it has both oral and parenteral formulations, excellent bioneutropenia and susceptibility to fluconazole could be appreciavailability, and a low level of toxicity [10, 11] . ated when the relationship between these variables and the However, fluconazole therapy may fail under certain circumrecovered Candida species (albicans vs. non-albicans) and stances. Colonization and infection with intrinsically resistant clinical response was examined (data not shown in table 3) .
Candida species such as C. krusei may develop after fluconaAlthough recovery from neutropenia seemed to be associated zole treatment [12, 13] . Moreover, prophylactic use of the drug with a favorable clinical response (P Å .04), when subgroup by patients with AIDS may even cause emergence of resistance analysis was performed this was valid only for patients infected among C. albicans isolates [14] . with a non-albicans strain (P Å .049); it was insignificant for Predicting the clinical outcome of fluconazole treatment by those infected with C. albicans (P Å .65). Therefore, multivaridetermination of MICs against the infecting yeasts has been ate analysis eliminated ''recovery from neutropenia'' as a significant variable for treatment success.
troublesome so far. This is mainly attributable to the fact that / 9c4a$$ap14 03-09-98 17:33:34 cida UC: CID host factors such as effective treatment of the underlying disAlthough our findings may suggest that species identification can assist in predicting the in vitro susceptibility pattern and ease, recovery from neutropenia, and removal of intravenous catheters may also influence the therapeutic outcome [5, 10, clinical outcome, such a prediction may not always be relevant since emergence of resistance to fluconazole among susceptible 15]. Assessment of relevant MIC breakpoints is another problem complicating the issue.
species (like C. albicans) may emerge in AIDS patients and others who receive long-term antifungal prophylaxis [14] . FurStudies have been carried out to define the correlation of clinical response with in vitro susceptibility in cases involving thermore, species like C. glabrata that are less susceptible to fluconazole may be associated with MIC values of §64 AIDS patients with oropharyngeal candidiasis [6] . The results have pointed out that there is a constant relationship between mg/mL [9] . This was the situation for one of the C. glabrata strains included in our study, which was isolated from a neutro-MIC and outcome when the MICs are interpreted in a dosedependent fashion, a finding suggesting that the tentative penic patient who did not respond to fluconazole therapy. None of our isolates was associated with an MIC of 16 -32 mg/mL, breakpoint should be chosen according to the achievable levels of fluconazole in blood.
so dose-dependent evaluation of the in vitro results was not applicable. The peak level of the drug is Ç6 mg/mL and 0 -30 mg/mL for dosages of 100 mg/d and 400 mg/d, respectively, suggesting As indicated in table 2, infection with some of the susceptible strains resulted in clinical failure, and with some resistant that isolates for which MICs are õ64 mg/mL can be inhibited when a 400-mg/d dosage of fluconazole is used [6, 7] . Howstrains clinical success could be achieved; this emphasizes the significance of multifactorial evaluation of the outcome of the ever, data obtained in another study could not correlate clinical outcome with in vitro MICs in cases involving AIDS patients infection. Not only the in vitro susceptibility pattern but also the host factors such as neutrophil count and management of with oropharyngeal candidiasis [16] . These data were similar to those of Rex et al. [5] , who studied candidemic nonneutropenic underlying disease should be taken into consideration to predict the clinical outcome. These data show that in vitro susceptibilpatients without AIDS.
Following these preliminary reports, the NCCLS antifungal ity results should still be viewed cautiously.
In conclusion, our results indicate that clinical outcome susceptibility testing subcommittee proposed interpretive MIC breakpoints for fluconazole that seemed to correlate the in vitro seems to be correlated with the in vitro fluconazole-susceptibility results for oropharyngeal candidiasis in severely ill patients results with the clinical outcome. According to these guidelines, strains for which the MIC values are £8 mg/mL and §64 when the proposed MIC breakpoint value of §64 mg/mL is validated. In vitro -in vivo correlation for non-krusei Candida mg/mL are interpreted as susceptible and resistant, respectively. MICs of 16 mg/mL and 32 mg/mL were considered to denote isolates associated with high MIC values should be evaluated to increase the predictive power of the currently available intersusceptibility, depending upon dose, on the basis of the data indicating clinical success with fluconazole at a dosage of pretive breakpoints. However, correlating the MIC of fluconazole with clinical outcome is not a totally clarified issue and ú100 mg/d. These results were more definite for C. albicans and oropharyngeal infections but not for non-albicans Candida requires complex evaluation of several factors. species and invasive infections. For C. krusei, the intrinsically resistant Candida species, this scale was not suggested and not
